Retatrutide vs Tirzepatide: Comparing Two Multi-Agonist Peptides

This forum is for structured, evidence-based discussion comparing Retatrutide and Tirzepatide — two of the most-discussed multi-receptor agonist peptides in current research.

Key Differences

Receptor targets: Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide adds a third target, glucagon receptor agonism, making it a triple agonist. Researchers post primary literature and trial data comparing how this third pathway affects outcomes in preclinical and early clinical models.

Trial stage: Tirzepatide has FDA-approved pharmaceutical forms (Mounjaro, Zepbound); Retatrutide remains in Phase 3 trials. Research-grade material for either compound is not the same product as the approved pharmaceutical and should not be treated as interchangeable.

Reported research findings: Share links to peer-reviewed studies, trial results, and dosing protocols used in published research. Avoid personal anecdotes framed as medical advice.

Related Discussions

See also: Research Compounds, Research Education, and the individual compound forums for Retatrutide and Tirzepatide.